Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2

Cell Death and Differentiation

Volumn 11, Issue 2, 2004, Pages 203-207

  Mori, E ^a   Thomas, M ^a   Motoki, K ^a   Nakazawa, K ^a   Tahara, T ^a   Tomizuka, K ^a   Ishida, I ^a   Kataoka, S ^a  

^a KIRIN BREWERY CO LTD   (Japan)

Author keywords

Hepatocyte; Human antibody; TRAIL; TRAIL R1; TRAIL R2

Indexed keywords

CASPASE; CYTOKINE RECEPTOR; DEATH RECEPTOR 4; DEATH RECEPTOR 5; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; ENDOTHELIUM CELL; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CULTURE; LIVER TOXICITY; NONHUMAN; PRIORITY JOURNAL; UMBILICAL VEIN;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; CASPASES; CELL LINE, TUMOR; FLOW CYTOMETRY; HEPATOCYTES; HUMANS; MICE; MICE, TRANSGENIC; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 0742272016     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401331     Document Type: Article

References (22)

1. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C and Smith CA (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682
2. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A and Ashkenazi A (1996) Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271: 12687-12690
3. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC and Lynch DH (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5: 157-163
4. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z and Schwall RH (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104: 155-162
5. Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J and Fox JA (2001) Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J. Pharmacol. Exp. Ther. 299: 31-38
6. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR and Strom SC (2000) Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med. 6: 564-567
7. Nitsch R, Bechmann I, Deisz RA, Haas D, Lehmann TN, Wendling U and Zipp F (2000) Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet 356: 827-828
8. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, Hillan K, Totpal K, DeForge L, Schow P, Hooley J, Sherwood S, Pai R, Leung S, Khan L, Gliniak B, Bussiere J, Smith CA, Strom SS, Kelley S, Fox JA, Thomas D and Ashkenazi A (2001) Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med. 7: 383-385
9. LeBlanc HN and Ashkenazi A (2003) Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 10: 66-75
10. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J and Dixit VM (1997) The receptor for the cytotoxic ligand TRAIL. Science 276: 111-113
11. Pan G, Ni J, Wei YF, Yu G, Gentz R and Dixit VM (1997) An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277: 815-818
12. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P and Ashkenazi A (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277: 818-821
13. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, Goodwin RG and Rauch CH (1997) TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 16: 5386-5397
14. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J and Hood L (1997) Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 7: 821-830
15. Screaton GR, Mongkolsapaya J, Xu XN, Cowper AE, McMichael AJ and Bell JI (1997) TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr. Biol. 7: 693-696
16. Griffith TS, Rauch CT, Smolak PJ, Waugh JY, Boiani N, Lynch DH, Smith CA, Goodwin RG and Kubin MZ (1999) Functional analysis of TRAIL receptors using monoclonal antibodies. J. Immunol. 162: 2597-2605
17. Chuntharapai A, Dodge K, Grimmer K, Schroeder K, Marsters SA, Koeppen H, Ashkenazi A and Kim KJ (2001) Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J. Immunol. 166: 4891-4898
18. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, Zhang H, Mountz JD, Koopman WJ, Kimberly RP and Zhou T (2001) Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat. Med. 7: 954-960
19. Ishida I, Tomizuka K, Yoshida H, Tahara T, Takahashi N, Ohguma A, Tanaka S, Umehashi M, Maeda H, Nozaki C, Halk E and Lonberg N (2002) Production of human monoclonal and polyclonal antibodies in TransChromo (TC) animals. Cloning Stem Cells 4: 91-102
20. Zhang XD, Nguyen T, Thomas WD, Sanders JE and Hersey P (2000) Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett. 482: 193-199
21. Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK and Huang HJ (2000) Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res. 60: 847-853
22. Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A and Tschopp J (1998) Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 187: 1205-1213